A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
Alla 75- aastastel II tüüpi diabeedi ja olulise suurte veresoonte haigusega patsientidel viidi läbi kardiovaskulaarse mõju uuring pioglitasooniga.